Integrating Genomics & Real-World Data to Predict Fam-Trastuzumab Deruxtecan Response in Metastatic Breast Cancer Across HER2 Subtypes - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Integrating Genomics & Real-World Data to Predict Fam-Trastuzumab Deruxtecan Response in Metastatic Breast Cancer Across HER2 Subtypes

2:30 pm - Tuesday 13th October 2026

Contextualizing the need for ADC biomarkers to identify optimized patient subpopulations
Leveraging real-world data and genomics to evaluate associations between somatic mutations and clinical outcomes in metastatic breast cancer patients treated with T-DXd across HER2 subtypes
Highlighting genomic findings to correlate T-DXd response and support further investigation of PIK3CA as a potential predictive biomarker of response in the HER2-low subgroup

Speakers:

Abraham Apfel

Abraham Apfel

Associate Director, Clinical Data Science

Eisai Co., Ltd.